$HQY

Fiore Michael Henry sold $298K of HQY

Fiore Michael Henry (EVP, CHIEF COMMERCIAL OFFICER) sold 3,142 shares of HEALTHEQUITY, INC. (HQY) at $95.00 ($0.30M total) on 2026-05-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fiore Michael Henry
Published Jun 2, 2026, 9:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 9:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$HQY
Neutral
medium confidence
Mentioned
$HQY
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HQYNeutralLow
01

Why it matters

The disclosed sale is under a pre-arranged 10b5-1 plan, typically viewed as lower information content than unscheduled selling.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure alone is unlikely to drive a fundamental repricing.

03

What to watch

The filing excerpt doesn’t state total compensation context, diversification needs, or whether other insiders are buying/selling around the same period.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed today; sale occurred on 2026-05-29

Background

The article is a SEC EDGAR Form 4 insider transaction disclosure for HEALTHEQUITY (HQY).

Company-level read

Ticker impact

$HQYNeutralMedium confidence
Context

HEALTHEQUITY’s EVP/Chief Commercial Officer sold 3,142 shares in an open-market transaction disclosed on SEC Form 4.

Expected impact

Likely limited near-term impact; any effect is more about positioning/flow than new fundamentals.

Evidence & confidence

Form 4 shows a scheduled 10b5-1 sale (not discretionary timing), with no accompanying earnings, guidance, or operational change in the filing excerpt.

Market effects

Minimal—this is company-specific insider activity with no sector-wide catalyst indicated.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with internal risk perceptions; traders may treat it as a mild caution signal.

Key entities

  • HEALTHEQUITY, INC.

    Subject of the Form 4 insider transaction; shares sold by an EVP/Chief Commercial Officer.

  • Fiore Michael Henry

    EVP, Chief Commercial Officer who sold 3,142 shares at $95.00 on 2026-05-29 (reported via Form 4 filed 2026-06-02).

Related articles

$HQYMed

HealthEquity rating upgraded by Moody’s on strong cash flow

Moody’s upgraded HealthEquity, Inc. (NASDAQ:HQY) corporate family rating to Ba2 from Ba3 and raised its probability of default rating to Ba2-PD from Ba3-PD. It also upgraded $600 million senior unsecured notes to Ba3 from B1, with outlook changed to stable. Moody’s cited stronger operating cash flow and BenefitWallet integration, plus improved leverage and liquidity.

$HQYMedAI 9/10

HealthEquity Q1 2027 Earnings Call: Complete Transcript - HealthEquity (NASDAQ: HQY)

HealthEquity reported fiscal 2027 first-quarter results, citing 7% year-over-year revenue growth and a record adjusted EBITDA margin of 46%, according to the company. It raised guidance to $1.41–$1.42B revenue and $625–$633M adjusted EBITDA. The firm said it expanded digital engagement and Marketplace, used AI for efficiency, saw HSA assets +19% and new HSA sales +15%, and increased its share repurchase authorization by $1B.